Sansheng Guojian (688336): Sales of marketed products are growing steadily, and many drug candidates are about to be marketed
Sansheng Guojian (688336): Sales of major products increased and varieties formed an echelon
Sansheng Guojian (688336): Focus on self-free circuit products+pipelines to build a self-defense matrix
Sansheng Guojian (688336) Company's First Coverage Report: New Pipelines Empower Medium- to Long-Term Development for Leading Companies on Self-Free Raceway
Sansheng Guojian (688336): The first quarterly report exceeded expectations, basic business is steady, and the follow-up self-exemption pipeline is progressing at an accelerated pace
Sansheng Guojian (688336): Performance exceeds expectations, core product revenue continues to grow at a high rate
Sansheng Guojian (688336): The beautiful start of the year is expected to continue to be rich in self-exemption pipelines
Sansheng Guojian (688336): Steady implementation of R&D to improve operational quality and efficiency
Sansheng Guojian (688336): Significant increase in performance IL-17 submitted a listing application at the end of 2017
Sansheng Guojian (688336): Performance is in line with expectations, self-preventing inflammation products are progressing steadily
Sansheng Guojian (688336): Veteran Self-Exemption Commercial Leader Skin Self-Exemption Creates a Second Curve
Sansheng Guojian (688336): Significant increase in performance and steady progress in the research pipeline
Sansheng Guojian (688336) First Coverage Report: A leader in the in-depth layout of the self-defense industry
Sansheng Guojian (688336): A leader in the in-depth layout of the self-defense industry
Sansheng Guojian (688336) Company News Review: Efficient operation, rapid increase in revenue and profit, free pipeline ready to go
Sansei Kuniken (688336): Q3 performance maintains a high growth rate, and the self-exemption pipeline is entering a harvest period one after another
Sansei Guojian (688336): Revenue and profit are growing steadily, and the self-exemption pipeline is progressing in an orderly manner
Sansei Kuniken (688336) 2023 Semi-Annual Report Review: Performance Exceeds Expectations, Pipeline Advances Rapidly
Sansei Guojian (688336): Performance is in line with expectations, biopharmaceuticals are growing strongly
Sansei Guojian (688336): 23H1 performance is growing rapidly, and the progress of the self-exemption pipeline is ahead
No Data